Company profile for Ideaya Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating predictive biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies. We are applying these capabilities ac...
IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating predictive biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies. We are applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways at the level of activated oncogenes or downstream signaling components and, synthetic lethality.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
7000 Shoreline Court, Suite 350 South San Francisco, CA 94080
Telephone
Telephone
(650) 443-6209
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-ind-submission-for-ide574-a-potential-first-in-class-kat67-dual-inhibitor-for-breast-and-lung-cancers-302637521.html

PR NEWSWIRE
10 Dec 2025

https://www.biospace.com/business/gsk-cuts-five-year-old-cancer-collaboration-with-ideaya

BIOSPACE
09 Dec 2025

https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-ind-clearance-for-ide034-a-potential-first-in-class-bispecific-b7h3ptk7-top1-adc-targeting-multiple-solid-tumor-types-302628524.html

PR NEWSWIRE
01 Dec 2025

https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302627243.html

PR NEWSWIRE
28 Nov 2025

https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-december-2025-investor-relations-events-302623457.html

PR NEWSWIRE
24 Nov 2025

https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-positive-phase-2-data-for-darovasertib-in-the-neoadjuvant-setting-of-primary-uveal-melanoma-in-a-proffered-paper-oral-presentation-at-esmo-2025-302588310.html

PR NEWSWIRE
20 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty